公开(公告)号：US20150191452A1

公开(公告)日：2015-07-09

申请号：US14589205

申请日：2015-01-05

Applicant: Bristol-Myers Squibb Company

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，可用于治疗中枢神经系统的各种疾病。

公开(公告)号：US20200069646A1

公开(公告)日：2020-03-05

申请号：US16555634

申请日：2019-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Steven P. Seitz ,  Susheel Jethanand Nara ,  Saumya Roy ,  Srinivasan Thangathirupathy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla

IPC: A61K31/415 ,  C07C275/42 ,  C07D231/12 ,  C07D401/12 ,  C07D403/12 ,  C07D261/08 ,  C07D277/22 ,  C07D285/08 ,  C07D211/60 ,  C07D317/50 ,  C07D307/36 ,  C07D333/54 ,  C07D231/56 ,  C07D221/22 ,  C07D471/04 ,  C07D487/04 ,  A61K31/17 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/42 ,  A61K31/426 ,  A61K31/433 ,  A61K31/357 ,  A61K31/341 ,  A61K31/381 ,  A61K31/5377

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

公开(公告)号：US20180312495A1

公开(公告)日：2018-11-01

申请号：US15767385

申请日：2016-10-13

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  John E. Macor

IPC: C07D413/04 ,  A61P25/24 ,  C07D413/14 ,  C07D413/12

CPC classification number: C07D413/04 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20180250283A1

公开(公告)日：2018-09-06

申请号：US15971067

申请日：2018-05-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20180110766A1

公开(公告)日：2018-04-26

申请号：US15846672

申请日：2017-12-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US09790169B2

公开(公告)日：2017-10-17

申请号：US15088211

申请日：2016-04-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: C07C229/42 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/395 ,  C07C255/58 ,  C07C275/40 ,  C07D205/04 ,  C07D211/14 ,  C07D239/47 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D309/04 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D309/14 ,  C07D407/12 ,  C07D487/08 ,  C07D265/30 ,  C07D207/08 ,  C07D211/08 ,  C07D307/22 ,  C07C255/57 ,  C07C235/38 ,  C07C235/56

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20170258777A1

公开(公告)日：2017-09-14

申请号：US15604904

申请日：2017-05-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D401/04 ,  C07D403/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20170231999A1

公开(公告)日：2017-08-17

申请号：US15584818

申请日：2017-05-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: A61K31/538 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20160081995A1

公开(公告)日：2016-03-24

申请号：US14882041

申请日：2015-10-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US08722670B2

公开(公告)日：2014-05-13

申请号：US13627130

申请日：2012-09-26

Applicant: Bristol-Myers Squibb Company

Inventor： Dalton King ,  Richard E. Olson ,  John E. Macor ,  Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier

IPC: C07D413/14 ,  C07D487/04 ,  A61K31/4709 ,  A61K31/4245

CPC classification number: C07D413/12 ,  C07D271/113 ,  C07D401/12 ,  C07D403/08 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，拮抗剂，可用于治疗中枢神经系统的各种疾病。